Remove 2009 Remove Biomarkers Remove Dementia
article thumbnail

APOE4 & Cardiovascular Risk

Dr. Paddy Barrett

Being a carrier of the APOE4 gene variant is associated with higher rates of the most common type of dementia, late-onset dementia. Of those with late-onset dementia, up to 65% are carriers of the APOE4 gene variant 1. Of those with late-onset dementia, up to 65% are carriers of the APOE4 gene variant 1. What to do?

article thumbnail

The legal case – naming a few names

Dr. Malcolm Kendrick

(2022-25) Swiss Reinsurance Company: £645K China Kadoorie Biobank (2002-ongoing) AstraZeneca: $300K Bayer AG: £300K GlaxoSmithKline: £3.6M Elinogrel feasibility trial (2010-2011) Novartis: £500K EMPA-KIDNEY (2017-ongoing) Boehringer Ingelheim: £106.3M Establishing Fuwai-Oxford research centre (2010-ongoing) Merck: £1.1M